By Carlo Martuscelli 
 

Roche Holding AG (RO.EB) said Monday that a phase 3 study combining cancer drugs Tecentriq and Avastin had met its primary targets, showing efficacy in patients with hepatocellular carcinoma.

The two drugs together increased overall as well as progression-free survival in patients with inoperable hepatocellular carcinoma who hadn't previously received systemic therapy, the pharmaceutical company said.

Roche said that a breakdown of the data will be presented at a coming medical conference.

"We are very pleased with the results of our study testing the combination of Tecentriq and Avastin, which marks the first treatment in more than a decade to improve overall survival in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy," said Chief Medical Officer Levi Garraway.

The company said it will submit the data from the study to health regulators globally, including in the U.S., Europe and China.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com; @carlomartu

 

(END) Dow Jones Newswires

October 21, 2019 01:29 ET (05:29 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Roche (QX) Charts.